Protein haploinsufficiency drivers identify MYBPC3 mutations that cause hypertrophic cardiomyopathy

Carmen Suay-CorrederaMaria Rosaria PricoloElias Herrero-GalanDiana Velazquez-CarrerasDavid Sanchez-OrtizDiego Garcia-GiustinianiJavier DelgadoJuan Jose Galano-FrutosHelena Garcia-CebolladaSilvia VilchesFernando DominguezMaria Sabater MolinaRoberto Barriales-VillaGiulia FrissoJavier SanchoLuis SerranoPablo Garcia-PaviaLorenzo MonserratJorge Alegre-Cebollada.

Abstract: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Mutations in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), are a leading cause of HCM. However, it remains challenging to define whether specific gene variants found in patients are pathogenic or not, limiting the reach of cardiovascular genetics in the management of HCM. Here, we have examined cMyBP-C haploinsufficiency drivers in 68 clinically annotated non-truncating variants of MYBPC3. We find that 45% of the pathogenic variants show alterations in RNA splicing or protein stability, which can be linked to pathogenicity with 100% and 94% specificity, respectively. Relevant for variant annotation, we uncover that 9% of non-truncating variants of MYBPC3 currently classified as of uncertain significance induce one of these molecular phenotypes. We propose that alteration of RNA splicing or protein stability caused by MYBPC3 variants provide strong evidence of their pathogenicity, leading to improved clinical management of HCM patients and their families.

Link a la publicación.